Evidence map›Paper›PMID 40008363›Full record

ArticleiScience2025

Multicenter study for CH-VAD as a fully magnetically levitated left ventricular assist device.

Yifan Lu, Shuanglei Zhao, Jie Han, Qiang Lv, Xin Du, Zhengdong Hua, Keli Huang, Zhenwei Ge, Xiaoning Sun, Dan Zhu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yifan LuHeart Failure and Valve Surgery Center, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
Shuanglei ZhaoHeart Failure and Valve Surgery Center, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
Jie HanHeart Failure and Valve Surgery Center, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
Qiang LvDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
Xin DuDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
Zhengdong HuaDepartment of Cardiac Surgery, Asia Heart Hospital, Wuhan 430010, China.
Keli HuangDepartment of Cardiac Surgery, Sichuan Provincial People's Hospital, Chengdu 610072, China.
Zhenwei GeDepartment of Cardiovascular Surgery, Henan Provincial Chest Hospital, Zhengzhou 450003, China.
Xiaoning SunDepartment of Cardiac Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Dan ZhuDepartment of Cardiovascular Surgery, Shanghai Chest Hospital, Shanghai 200030, China.
Yongfeng ShaoDepartment of Cardiovascular Surgery, Jiangsu Provincial People's Hospital, Nanjing 212028, China.
Hongjia ZhangHeart Failure and Valve Surgery Center, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
Ming GongHeart Failure and Valve Surgery Center, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The CH-VAD is a fully magnetically levitated left ventricular assist device (LVAD) designed for optimized hemocompatibility. This study evaluates the clinical outcomes of 77 patients implanted with the CH-VAD across seven centers in China from June 2022 to June 2024. Patients had a mean age of 57.5 years, primarily classified as INTERMACS 2 or 3, with dilated and ischemic cardiomyopathy as the main causes of heart failure (HF). The study reported a 91.6% survival rate at both 6-month and 1-year follow-ups, aligning with international LVAD outcomes. Key adverse events were infrequent, including low rates of right HF, reoperation for bleeding, and driveline infection. Importantly, no pump thrombosis or device failures were noted. The results suggest that the CH-VAD is a reliable and effective long-term mechanical circulatory support option for end-stage HF patients in China, warranting further studies for long-term efficacy evaluation.

Indexed as

Applied sciencesHealth sciencesNatural sciences

Identifiers

PMID40008363
PMCPMC11850155

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.